Real-world disease, patient characteristics and treatment patterns in patients with Non-Small Cell Lung Cancer and extensive stage Small cell lung cancer in Belgium [AIBED]

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  OSIMERTINIB

  DURVALUMAB
• Medical condition to be studied:
  Non-small cell lung cancer

  Small cell lung cancer

Population studied

• Short description of the study population:
  Non-small cell lung cancer and small cell lung cancer diagnosed between 1 January 2019 and 31 December 2021.
• Estimated number of subjects:
  2000

Study design details

• Study design:
  Multicenter study (n = 5) analyzing routinely collected data from pseudonymized electronic health records (EHRs) using natural language processing (NLP) for unstructured sources. The algorithm mapped variables to a standard terminology, generating OMOP CDM databases, validated per hospital.
• Main study objective:
  This study describes the following in Belgian patients with lung cancer for specific subpopulations of interest (Patients with stage IB-IIIB NSCLC, stage III unresected NSCLC, Stage IV NSCLC, or ES-SCLC):; • Demographics; • Biomarker testing with focus on EGFR and PD-L1; • Treatment patterns with focus on durvalumab and osimertinib
• Setting:
  Belgium, diagnosis between 2019 and 2021
• Summary results:
  We included 1952 patients, of whom 87% (1699) had NSCLC and 13% (253) SCLC (86.6% ES-SCLC). Stage IB-IIIB resected NSCLC included 17.3%, unresected stage III NSCLC 12.3%, and stage IV NSCLC 45.0% of NSCLC patients. Brain metastasis around diagnosis was reported in 16.4% of stage IV NSCLC (22.3% in EGFR mutated) and 15.1% of ES-SCLC patients. Across NSCLC subcohorts, 53.9% of patients had a programmed death-ligand 1 (PD-L1)- positive tumor (≥1%) and 12.7% an EGFR mutation-positive tumor. In stage IB-IIIB resected NSCLC patients, resection status was retrieved for 83.0% of patients, of whom 93.0% had complete resection. Among 327 stage III NSCLC patients, 63.9% (n = 209) were unresected, 36.7% (n = 120) had a PD-L1-positive tumor, 18.3% (n = 60) completed chemoradiotherapy, and 11.3% (n = 37) initiated durvalumab